MedPath

University Of Pittsburgh

University Of Pittsburgh logo
🇺🇸United States
Ownership
Private
Established
1787-02-28
Employees
10K
Market Cap
-
Website
http://www.pitt.edu

Clinical Trials

1.4k

Active:44
Completed:946

Trial Phases

6 Phases

Early Phase 1:17
Phase 1:79
Phase 2:87
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1029 trials with phase data)• Click on a phase to view related trials

Not Applicable
744 (72.3%)
Phase 2
87 (8.5%)
Phase 1
79 (7.7%)
Phase 4
67 (6.5%)
Phase 3
35 (3.4%)
Early Phase 1
17 (1.7%)

How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding

Not Applicable
Not yet recruiting
Conditions
Urinary Retention
Urinary Tract Infection (Diagnosis)
Postpartum Care
Voiding Dysfunction
Postpartum Acute Urinary Retention
First Posted Date
2025-08-15
Last Posted Date
2025-08-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
564
Registration Number
NCT07125326
Locations
🇺🇸

UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

Not Applicable
Not yet recruiting
Conditions
Cardiometabolic Health
First Posted Date
2025-08-13
Last Posted Date
2025-08-13
Lead Sponsor
University of Pittsburgh
Target Recruit Count
15
Registration Number
NCT07121010
Locations
🇺🇸

UPMC Montefiore - Clinical and Translational Research Center (CTRC), Pittsburgh, Pennsylvania, United States

Psychosocial and Behavioral Intervention for Stem Cell Transplant Patients and Their Family Caregivers

Not Applicable
Recruiting
Conditions
Stem Cell Transplant
Hematopoetic Stem Cell Transplant
Hematopoetic Stem Cell Transplantation
First Posted Date
2025-08-06
Last Posted Date
2025-08-06
Lead Sponsor
University of Pittsburgh
Target Recruit Count
208
Registration Number
NCT07107165
Locations
🇺🇸

University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Remote Mindfulness Training Following Early Life Adversity 2

Not Applicable
Recruiting
Conditions
Stress
Mindfulness
Early Life Adversity
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
University of Pittsburgh
Target Recruit Count
15
Registration Number
NCT07085052
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support

Not Applicable
Not yet recruiting
Conditions
People Who Use Opioids/People With Opioid Use Disorder (OUD)
First Posted Date
2025-07-20
Last Posted Date
2025-08-12
Lead Sponsor
University of Pittsburgh
Target Recruit Count
536
Registration Number
NCT07073924
Locations
🇺🇸

Latterman Family Health Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Center for Psychiatric And Chemical Dependency Services, Pittsburgh, Pennsylvania, United States

🇺🇸

Internal Medicine Recovery Engagement Program, Pittsburgh, Pennsylvania, United States

and more 1 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 274
  • Next

News

Medicus Pharma and HelixNano Partner to Develop Needle-Free, Heat-Stable mRNA Vaccines

Medicus Pharma and HelixNano have signed a non-binding memorandum of understanding to develop thermostable mRNA vaccines that eliminate cold-chain storage requirements.

Sucralose Artificial Sweetener Reduces Cancer Immunotherapy Effectiveness Through Gut Microbiome Disruption

University of Pittsburgh researchers found that sucralose consumption is associated with worse overall response and progression-free survival in cancer patients receiving anti-PD-1 immunotherapy.

Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy

Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.

FDA Approves IDE for ECM Therapeutics' Novel Hydrogel Treatment for Anorectal Fistulas

ECM Therapeutics has received FDA Investigational Device Exemption approval for ECMT-100, a regenerative hydrogel derived from extracellular matrix designed to treat anorectal fistulas non-surgically.

Magnetic Silk Microparticles: A Breakthrough for Targeted Drug Delivery

University of Pittsburgh researchers have developed silk iron microparticles (SIMPs) that can be magnetically guided through the body to deliver treatments directly to disease sites like tumors or aneurysms.

American Heart Association Awards $1M to Study GLP-1 Medications' Impact on Cardiovascular Risk

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

Elahere Demonstrates Significant Survival Benefit in Phase III MIRASOL Trial for Platinum-Resistant Ovarian Cancer

AbbVie's final analysis of the phase III MIRASOL trial confirms Elahere (mirvetuximab soravtansine) provides superior efficacy compared to chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer patients.

Novel Spinal Cord Stimulation Shows Promise in Treating Spinal Muscular Atrophy

A groundbreaking pilot study demonstrates that spinal cord implants delivering low-level electrical stimulation helped three adults with spinal muscular atrophy regain muscle function and mobility.

Experimental Nasal Swab Distinguishes Asthma Subtypes in Novel Diagnostic Approach

A novel nasal swab shows promise in differentiating between T2-high and T2-low asthma, offering a more precise diagnosis compared to current methods.

Novel Compound SYM2081 Shows Promise in Treating Inflammatory Skin Conditions Like Rosacea

Researchers have identified a novel compound, SYM2081, that targets mast cells to reduce inflammation in skin conditions like rosacea.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.